To read more on this topic click here.
Inhalable drug given green light
Author: Simge Eva DoganPublished: 9 January 2019
Prep: Cook: Serves:
The US Food and Drug Administration (FDA) has approved INBRIJA – an inhalable drug created by US biotech company Acorda Therapeutics – for intermittent treatment.
INBRIJA is designed to treat Parkinson’s symptoms that occur between oral doses of medication, which are known as ‘off’ episodes. The drug has been approved by the FDA and – after a clinical study involving 900 people with Parkinson’s – is expected to be available in 2019.
Todd Sherer, CEO of The Michael J Fox Foundation, who funded early trials of the powder, said: “Despite being on treatment, patients may experience OFF periods as Parkinson’s progresses, which can be disruptive.
“We knew we had to help address this unmet need, and this approval is a significant step forward for the community as it provides a new option to manage these gaps in symptom control.”
For more information on Parkinson’s medication please visit Parkinson’s Europe website.
Researchers create Parkinson’s-resistant stem cells
Memory loss could be an indication of Parkinson’s
Share this story
Ryan Reynolds in emotional plea as dad loses fight with Parkinson’s disease
Actor honours father and urges donations for Parkinson’s researchREAD MORE
Recipes & nutrition
How to choose the best nutrient-rich foods for Parkinson’s
Expert guide: foods that could help your Parkinson’s symptomsREAD MORE
Parkinson’s in the news: May
A roundup of Parkinson’s news stories in MayREAD MORE